fueling up

Houston company secures $100M to fund solar projects across New York

Catalyze’s proprietary suite of technology will bring solar development practices to Lancaster and Amherst areas. Photo courtesy of Catalyze

Houston’s Catalyze announced that it secured $100 million in financing from NY Green Bank to support a 79 megawatt portfolio of community distributed generation solar projects across the state of New York.

The loan is part of Catalyze’s increased presence in New York State with operational projects coming to Lancaster and Amherst. Catalyze’s proprietary suite of technology will bring solar development practices to the area.

Catalyze is a Houston-headquartered clean energy transition company that builds, owns, finances, and operates solar and battery storage systems. Catalyze is backed by leading energy investors EnCap Investments L.P. and Actis. NY Green Bank is a division of the New York State Energy Research and Development Authority.

The deal aims to advance New York State’s Climate Leadership and Community Protection Act goal of installing six gigawatts of distributed solar by 2025. This is part of a larger goal to 10 GW by 2030.

Catalyze owns two proprietary technologies in REenergyze, which is an origination-to-operations software integration platform to accelerate and scale nationwide adoption of commercial and industrial solar and storage, and SolarStrap. SolarStrap isa mounting technology to install rooftop panels.

“We are excited to leverage our extensive community solar expertise to ensure the success of NY Green Bank’s term loan supporting a community distributed generation (CDG) portfolio,” Jared Haines CEO of Catalyze, says in a news release. “CDG is one of the most effective means of making solar energy more accessible to low-to-moderate income communities, and we look forward to how this partnership will support both the goals of NY Green Bank and New York State.”

Trending News

A View From HETI

Cemvita has named a new leader in Brazil. Photo via cemvita.com

Houston industrial biotech company Cemvita has announced two strategic moves to advance its operations in Brazil.

The company, which utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals, acquired a complementary technology that expands its IP and execution of scale-up capacity, according to a news release. The acquisition will bring additional synthetic biology toolsets that Cemvita believes will assist with compressing and commercializing timelines.

The company also appointed Luciano Zamberlan as vice president of operations based in Brazil.

Zamberlan will lead operational execution, site readiness and early commissioning activities in Brazil. He brings more than 20 years of experience in biotechnology to the role. He recently served as director of engineering at Raízen, Brazil’s largest ethanol producer and the world’s largest producer of sugarcane ethanol. At Raízen, he coordinated the implementation of four greenfield plants and oversaw operational teams and process optimization for second-generation ethanol (E2G) and biogas.

“I am very pleased to join Cemvita, a company at the forefront of transforming waste into valuable, sustainable resources,” Zamberlan said in the release. “My expertise in scaling-up innovation, coupled with my experience in structuring and commissioning greenfield industrial operations, is perfectly aligned with Cemvita's mission and I'm eager to bring my energy and drive to accelerate Cemvita's industrial performance and contribute for a circular future.”

Cemvita expanded to Brazil in January to help capitalize on the country’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, enacted in 2024. The law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

“These steps enable us to augment Brazil’s longstanding bioindustrial ecosystem with next-generation capabilities, reducing early commercialization risk and expanding optionality for future product platforms,” Marcio Silva, CTO of Cemvita, said in the news release. “Together, they strengthen our ability to move from proof-of-concept to industrial reality.”

Trending News